Retaane® in Age-Related Macular Degeneration
Phase 2
Completed
- Conditions
- Age Related Macular Degeneration
- Interventions
- Drug: juxtascleral depot injection of Retaane
- Registration Number
- NCT00569569
- Lead Sponsor
- Rudolf Foundation Clinic
- Brief Summary
The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.
While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.
Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- rejection of intravitreal injections
- presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration
Exclusion Criteria
- conditions precluding judgement of the fundus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 juxtascleral depot injection of Retaane Patients treated with Retaane
- Primary Outcome Measures
Name Time Method Increase in VA 6 months
- Secondary Outcome Measures
Name Time Method Decrease in Macula Edema 6 months